Urol. praxi, 2012; 13(5): 214-217

Systemic enzyme therapy in urological practice

MUDr.Karel Nouza, DrSc.
Centrum klinické imunologie, Praha

Systemic (oral – in English literature) enzyme therapy (SET or OET) is defined as therapeutic method using oral administration of combined

enzyme mixtures in form of acidoresistant tablets. A part of enzymes administered by this way is absorbed in small intestine and have

systemic effect. The medicinal drugs for SET were registered by SÚKL during ninetieths of past century. They found their firm position

in therapeutic list of many medical branches despite of initial negative posture of a part of specialists. Within registered indications the

medical drugs for SET have their application also in urology – they are used in the treatment of infections, acute and chronic inflammations

and also in operations and postoperative conditions. This article presents review of current knowledge focused on mechanisms of

SET medical drugs action and the list of clinical trials endorsing their application as a supportive treatment in urology.

Keywords: systemic (oral) enzyme therapy, inflammations of the urinary tract, infammations of prostate

Published: October 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nouza K. Systemic enzyme therapy in urological practice. Urol. praxi. 2012;13(5):214-217.
Download citation

References

  1. Lincová D, Farghali H (ed.). Základní a aplikovaná farmakologie, druhé vydání, Praha, Galén, 2007: 672.
  2. Wobenzym - Summary of product characteristics. MUCOS Pharma GmbH & Co. http://www.sukl.cz/download/spc/SPC12629.pdf.
  3. Phlogenzym - Summary of product characteristics. MUCOS Pharma GmbH & Co. http://www.sukl.cz/download/spc/SPC12626.pdf.
  4. Castell JV, Friedrich G, Kuhn CS, Poppe GE. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol. 1997; 273(1 Pt 1): G139-146. Go to original source... Go to PubMed...
  5. James K. Interactions between cytokines and alfa2-macroglobulin. Immunol Today 1990; 11: 163-166. Go to original source... Go to PubMed...
  6. Nouza K, Nouza M. Zánět optimalizující a imunitu normalizující působení kombinací proteolytických enzymů. Alergie 2002; 4(4): 326-329.
  7. Targoni OS, Tary-Lehmann M, Lehmann PV. (1999) Prevention of Murine EAE by Oral Hydrolytic Enzyme Treatment. J Autoimmun 12(3): 191-198. Go to original source... Go to PubMed...
  8. Lauer D, Müller R, Cott C, Otto A, Naumann M, Birkenmeier G. Modulation of growth factor binding properties of alpha2-macroglobulin by enzyme therapy. Cancer Chemother Pharmacol. 2001; 47(Suppl): S4-9. Go to original source... Go to PubMed...
  9. Olejár T, Nouza K. Thrombin and trypsin receptors: The same mechanism of signalling on cellular surfaces. Bratisl. Lek. Listy 1999; 100: 75-79. Go to PubMed...
  10. Ernst E. Oral therapy with proteolytic enzymes: Effects on hemorheological parameters. Perfusion 1994; 12: 440-441.
  11. Vinzenz K. Odembehandlung bei chirurgischen Eingrriffen mit hydrolytischnen Enzymen. Chirurgische Zahnheilkunde 1991; 7: 1053-1064.
  12. Kameníček V, Holáň P, Fran?k P. Systémová enzymoterapie v léčbě a profylaxi potraumatických a pooperačních otoku. Acta Chir OrthopTraumatol Cech. 2001; 68(1): 45-49.
  13. Barsom S, Sasse-Rollenhagen K, Bettermann A. Zur Behandlung von Zystitiden und Zystopyelitiden mit hydrolytischen Enzymen. Erfahrungsheilkunde. 1983; 32(3): 125-129.
  14. Schlüter P, Stauder G. Harnwegsinfektionen - Behandlung mit hydrolytischen Enzymen. TW Urologie Nephrologie, 1996; 8: 276-279.
  15. Sökeland J. Enzyme Therapy of Patients with Acute Hemorrhagic Cystitis. Randomised, Placebo-controlled, Clinical, Double-blind Multicenter Study of Phase III According to the European Standard of Good Practice, 1997; MU-695 416.
  16. Barsom S, et al. Erfolgreiche Prostatitisbehandlung mit hydrolytischen Enzymen. Erfahrungsheilkunde, 1982; 31: 2.
  17. Rugendorff EW, Burghele A, Schneider HJ. Behandlung der chronischen abakteriellen Prostatitis mit hydrolytischen Enzymen. Der Kassenarzt, 1986; 26(14): 43-51.
  18. Schlüter P. Efficacy and tolerance of oral enzyme therapy in chronic prostatitis. Results of a double-blind therapy study. European Journal for Infectious and Immunological Diseases, 1998; 2: 57-69.
  19. Tkachuk VN, Lukianov AE, Noskov NIu. Místo systémové enzymoterapie v komplexní léčbě nemocných chronickou prostatidou. Vrachebnoe soslovie. 2007; 5: 2-7.
  20. Belej K. Prostatitický syndrom - syndrom chronické pánevní bolestí Urolog. Praxi, 2007; 8(4): 153-157.
  21. Sukhikh GT, Loginova NS, Faizullin LZ, Zdanov AV, Malinina EV, Bozedomov VA. The use of Wobenzym(R) to facilitate interferon synthesis in the treatment of chronic urogenital chlamydiosis. Int. J. Immunotherapy, 1997, XIII(3/4): 131-133.
  22. Förstl M, Kalousek I, Navrátil P, Štěpánová V, Fajfr M. Zkušenosti s enzymoterapií v rámci komplexní léčby urogenitálních infekcí Chlamydia trachomatis. Urolog. Praxi, 2006; 5: 243-245.
  23. Förstl M, Förstlová M, Ryšková O, Kalousek I, Navrátil P. Enzymoterapie urogenitálních infekcí Chlamydia trachomatis. Urolog. Praxi, 2011; 12(3): 180-182.
  24. Bartoníčkova K. Co by měl urolog vědět o chlamydiových infekcich - přehled současného stavu. Urolog. Praxi, 2003; 3: 94-98.
  25. Matoušková M, Hanuš M. Chlamydia trachomatis - postrach urologické ambulance? Urolog. Praxi, 2009; 10(2): 60-64.
  26. ##
  27. Naber KG, Schaeffer AJ, Heyns CF, Matsumoto T, Shoskes DA, Bjerklund Johansen TE. Urogenital Infections. International Consultations on Urogenital Infections. I ed., 2010, EAU.
  28. Heřt J. Alternativní medicína a léčitelství. Kritický pohled.
  29. http://www.sysifos.cz/files/Alternativni_medicina_Hert.pdf.




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.